Amgen, a leading American multinational biopharmaceutical company based in Thousand Oaks, California, and one of the largest independent biotechnology companies globally, has announced plans to establish a new technology and innovation hub in Hyderabad, Telangana.
The facility, named Amgen India, will enhance the company’s digital capabilities globally and support the advancement of Amgen’s medicine pipeline. The site, which can accommodate up to 3,000 employees, is expected to be operational in 2024.
On August 9, 2024, Chief Minister A. Revanth Reddy and Industries Minister Duddilla Sridhar Babu met with Dr. David Reese and Mr. Som Chattopadhyay at Amgen’s R&D site in San Francisco to solidify their commitment to selecting Hyderabad for this new innovation hub.
IT and Industries Minister Sridhar Babu expressed excitement about Amgen’s decision to establish Amgen India in Hyderabad, viewing it as a strong endorsement of Telangana’s growing life sciences ecosystem. He emphasized the government’s commitment to partnering with Amgen to ensure the site’s success, marking the start of a promising long-term collaboration focused on building a healthier future.
The Chief Minister highlighted the significance of this development, noting the pride in having one of the world’s leading biotech companies choose Hyderabad for its first development facility in Telangana. He pointed out that Amgen’s new site reinforces the city’s status as a hub for innovation and technology, welcoming the global biotech leader whose mission to serve patients will inspire the region’s top technology talent.
Hyderabad was chosen for its exceptional talent pool in medicine, life sciences, and data sciences, as well as its rapid advancements in Artificial Intelligence (AI). The site, which will become operational in Q4 2024, will offer roles that enhance Amgen’s business in areas like AI, data science, life science, and other global capabilities over time.
David M. Reese, M.D., executive vice president and chief technology officer at Amgen, remarked on the significance of this expansion, noting that the convergence of biotechnology and technology enables Amgen to work with greater speed and efficiency at a time when innovation is crucial to addressing the needs of an aging global population.
To oversee Amgen’s growing presence in India, Som Chattopadhyay has been appointed as the national executive for India. Amgen employs nearly 27,000 people and operates in approximately 100 countries and regions worldwide.
